NASDAQ:ONCT Oncternal Therapeutics (ONCT) Stock Forecast, Price & News $0.31 0.00 (0.00%) (As of 02:13 PM ET) Add Compare Share Share Today's Range$0.30▼$0.3350-Day Range$0.29▼$0.4552-Week Range$0.26▼$1.33Volume70,570 shsAverage Volume336,254 shsMarket Capitalization$18.29 millionP/E RatioN/ADividend YieldN/APrice Target$4.10 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Oncternal Therapeutics MarketRank™ ForecastAnalyst RatingHold2.17 Rating ScoreUpside/Downside1,160.8% Upside$4.10 Price TargetShort InterestHealthy0.51% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.63) to ($0.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.88 out of 5 starsMedical Sector652nd out of 963 stocksPharmaceutical Preparations Industry295th out of 451 stocks 3.1 Analyst's Opinion Consensus RatingOncternal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 1 buy rating, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.10, Oncternal Therapeutics has a forecasted upside of 1,160.8% from its current price of $0.33.Amount of Analyst CoverageOncternal Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.51% of the outstanding shares of Oncternal Therapeutics have been sold short.Short Interest Ratio / Days to CoverOncternal Therapeutics has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Oncternal Therapeutics has recently increased by 0.61%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldOncternal Therapeutics does not currently pay a dividend.Dividend GrowthOncternal Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ONCT. Previous Next 2.2 News and Social Media Coverage News SentimentOncternal Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Oncternal Therapeutics this week, compared to 1 article on an average week.Search Interest5 people have searched for ONCT on MarketBeat in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Oncternal Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.00% of the stock of Oncternal Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 16.05% of the stock of Oncternal Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Oncternal Therapeutics are expected to grow in the coming year, from ($0.63) to ($0.43) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Oncternal Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oncternal Therapeutics is -0.43, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOncternal Therapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Oncternal Therapeutics (NASDAQ:ONCT) StockOncternal Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial. It is also developing ONCT-808, a chimeric antigen receptor T-cells (CAR-T), which is in Phase 1/2 clinical trial for the treatment of hematologic malignancies and solid tumors, as well as targets ROR1; and ONCT-534, a dual-action androgen receptor inhibitor product candidate in preclinical development for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. Oncternal Therapeutics, Inc. has license agreements with the Regents of the University of California; Georgetown University; The University of Texas MD Anderson Cancer Center; Shanghai Pharmaceutical (USA) Inc.; and University of Tennessee Research Foundation. Oncternal Therapeutics, Inc. has a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1. The company is headquartered in San Diego, California.Read More ONCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ONCT Stock News HeadlinesSeptember 20, 2023 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Receives New Coverage from Analysts at StockNews.comSeptember 19, 2023 | americanbankingnews.comOncternal Therapeutics (NASDAQ:ONCT) Lifted to Buy at HC WainwrightSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."September 18, 2023 | msn.comHC Wainwright & Co. Upgrades Oncternal Therapeutics (ONCT)September 18, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Argenx Se (ARGX), Innate Pharma (IPHA)September 17, 2023 | finance.yahoo.comWe're A Little Worried About Oncternal Therapeutics' (NASDAQ:ONCT) Cash Burn RateSeptember 9, 2023 | msn.comCantor Fitzgerald Reiterates Oncternal Therapeutics (ONCT) Neutral RecommendationSeptember 7, 2023 | finance.yahoo.comOncternal Therapeutics Announces its Prostate Cancer Scientific Advisory BoardSeptember 27, 2023 | Wall Street Fundamentals (Ad)The "Plug and Play" Model Putting Online Giants to ShameWhile e-commerce has been undergoing a turbulent time, a "simple" model has grown 4X faster than Amazon over the last 3 years. Applying this model to high-margin, recession-resistant businesses has shown to be profitable. But that's just the beginning of explaining the 400+% growth - and potential - of this "diamond in the rough."August 12, 2023 | finance.yahoo.comQ2 2023 Oncternal Therapeutics Inc Earnings CallAugust 11, 2023 | finance.yahoo.comOncternal Therapeutics Provides Business Update and Announces Second Quarter 2023 Financial ResultsAugust 9, 2023 | markets.businessinsider.comWhat Wall Street expects from Oncternal Therapeutics's earningsAugust 3, 2023 | finance.yahoo.comOncternal Therapeutics Receives FDA Study May Proceed Letter for ONCT-534, its Novel Dual-action Androgen Receptor Inhibitor, for the Treatment of Patients with Advanced Prostate CancerAugust 3, 2023 | finance.yahoo.comOncternal Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial ResultsJuly 27, 2023 | finance.yahoo.comONCT - Oncternal Therapeutics, Inc.June 21, 2023 | markets.businessinsider.comKyowa Kirin Appoints Gunnar F. Kaufmann, Ph.D., as Chief Research Officer, North AmericaJune 10, 2023 | morningstar.comOncternal Therapeutics Inc ONCT Stock QuoteJune 8, 2023 | finance.yahoo.comOncternal Therapeutics Announces First Patient Dosed in Phase 1/2 Study of ROR1 targeting autologous CAR T, ONCT-808, in patients with relapsed or refractory aggressive B-cell lymphomaJune 6, 2023 | msn.comHC Wainwright & Co. Reiterates Oncternal Therapeutics (ONCT) Neutral RecommendationJune 6, 2023 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for Oncternal Therapeutics (ONCT)May 31, 2023 | finance.yahoo.comOncternal Therapeutics to Participate at the 2023 Jefferies Healthcare ConferenceMay 10, 2023 | markets.businessinsider.comBTIG Sticks to Their Buy Rating for Shattuck Labs (STTK)May 9, 2023 | markets.businessinsider.comBTIG Keeps Their Buy Rating on Xencor (XNCR)May 6, 2023 | finance.yahoo.comOncternal Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS In LineMay 4, 2023 | msn.comOncternal Therapeutics GAAP EPS of -$0.20 in-line, revenue of $0.2M beats by $0.06MMay 4, 2023 | finance.yahoo.comOncternal Therapeutics Provides Business Update and Announces First Quarter 2023 Financial ResultsMay 4, 2023 | msn.comOncternal Therapeutics: Q1 Earnings InsightsSee More Headlines Receive ONCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oncternal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ONCT Company Calendar Last Earnings8/10/2023Today9/27/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ONCT CUSIPN/A CIK1260990 Webwww.oncternal.com Phone(858) 434-1113Fax901-844-8075Employees30Year FoundedN/APrice Target and Rating Average Stock Price Forecast$4.10 High Stock Price Forecast$9.00 Low Stock Price Forecast$1.30 Forecasted Upside/Downside+1,222.6%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($0.76) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-44,170,000.00 Net Margins-4,985.85% Pretax Margin-4,985.85% Return on Equity-75.67% Return on Assets-67.71% Debt Debt-to-Equity RatioN/A Current Ratio10.36 Quick Ratio10.37 Sales & Book Value Annual Sales$1.49 million Price / Sales12.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book0.29Miscellaneous Outstanding Shares58,970,000Free Float54,251,000Market Cap$18.28 million OptionableNot Optionable Beta1.54 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. James B. Breitmeyer M.D. (Age 69)Ph.D., Pres, CEO & Director Comp: $814.67kDr. Salim Yazji M.D. (Age 54)Chief Medical Officer Comp: $549.21kMr. Richard G. Vincent CPA (Age 59)CFO & Treasurer Dr. Rajesh Krishnan Ph.D. (Age 50)Chief Technology Officer Mr. Chase C. Leavitt (Age 41)Gen. Counsel & Sec. Mr. Pablo UrbanejaSr. VP of Corp. Devel.More ExecutivesKey CompetitorsVirios TherapeuticsNASDAQ:VIRIHepion PharmaceuticalsNASDAQ:HEPAAlzamend NeuroNASDAQ:ALZNMustang BioNASDAQ:MBIOAcasti PharmaNASDAQ:ACSTView All CompetitorsInsiders & InstitutionsBlackRock Inc.Sold 125,460 shares on 8/11/2023Ownership: 1.338%Richmond Brothers Inc.Bought 252,670 shares on 8/11/2023Ownership: 0.496%Renaissance Technologies LLCBought 31,900 shares on 8/11/2023Ownership: 0.489%Acadian Asset Management LLCSold 57,644 shares on 8/7/2023Ownership: 0.184%Gunnar F KaufmannBought 3,000 shares on 6/14/2023Total: $1,080.00 ($0.36/share)View All Insider TransactionsView All Institutional Transactions ONCT Stock - Frequently Asked Questions Should I buy or sell Oncternal Therapeutics stock right now? 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oncternal Therapeutics in the last year. There are currently 5 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ONCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ONCT, but not buy additional shares or sell existing shares. View ONCT analyst ratings or view top-rated stocks. What is Oncternal Therapeutics' stock price forecast for 2023? 6 brokerages have issued 1-year price targets for Oncternal Therapeutics' stock. Their ONCT share price forecasts range from $1.30 to $9.00. On average, they expect the company's stock price to reach $4.10 in the next twelve months. This suggests a possible upside of 1,222.6% from the stock's current price. View analysts price targets for ONCT or view top-rated stocks among Wall Street analysts. How have ONCT shares performed in 2023? Oncternal Therapeutics' stock was trading at $1.00 on January 1st, 2023. Since then, ONCT shares have decreased by 69.0% and is now trading at $0.31. View the best growth stocks for 2023 here. When is Oncternal Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our ONCT earnings forecast. How were Oncternal Therapeutics' earnings last quarter? Oncternal Therapeutics, Inc. (NASDAQ:ONCT) announced its quarterly earnings data on Thursday, August, 10th. The company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.02. The company had revenue of $0.11 million for the quarter, compared to the consensus estimate of $0.21 million. Oncternal Therapeutics had a negative net margin of 4,985.85% and a negative trailing twelve-month return on equity of 75.67%. What other stocks do shareholders of Oncternal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Oncternal Therapeutics investors own include Overstock.com (OSTK), NVIDIA (NVDA), OPKO Health (OPK), Advanced Micro Devices (AMD), QUALCOMM (QCOM), Avadel Pharmaceuticals (AVDL), Aldeyra Therapeutics (ALDX), Boeing (BA), CASI Pharmaceuticals (CASI) and Dynavax Technologies (DVAX). What is Oncternal Therapeutics' stock symbol? Oncternal Therapeutics trades on the NASDAQ under the ticker symbol "ONCT." Who are Oncternal Therapeutics' major shareholders? Oncternal Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (1.34%), Richmond Brothers Inc. (0.50%), Renaissance Technologies LLC (0.49%) and Acadian Asset Management LLC (0.18%). Insiders that own company stock include Chase C Leavitt, Chase C Leavitt, David F Hale, Gunnar F Kaufmann, James B Breitmeyer, Richard G Vincent and Salim Yazji. View institutional ownership trends. How do I buy shares of Oncternal Therapeutics? Shares of ONCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Oncternal Therapeutics' stock price today? One share of ONCT stock can currently be purchased for approximately $0.31. How much money does Oncternal Therapeutics make? Oncternal Therapeutics (NASDAQ:ONCT) has a market capitalization of $18.28 million and generates $1.49 million in revenue each year. The company earns $-44,170,000.00 in net income (profit) each year or ($0.76) on an earnings per share basis. How can I contact Oncternal Therapeutics? Oncternal Therapeutics' mailing address is 12230 EL CAMINO REAL SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.oncternal.com. The company can be reached via phone at (858) 434-1113, via email at investor.relations@oncternal.com, or via fax at 901-844-8075. This page (NASDAQ:ONCT) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncternal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.